117833-18-8Relevant articles and documents
VEGF NEUTRALIZING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS
-
Page/Page column 146; 147, (2014/05/07)
The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.
N-acetylaspartylglutamic acid and its β-isomer
Piotrovskii, L. B.,Dumpis, M. A.,Poznyakova, L. N.,Aleksandrova, L. N.,Sepetov, N. F.
, p. 96 - 100 (2007/10/02)
The α-isomer is predominantly formed in the synthesis of N-acetylaspartylglutamic acid and its β-isomer upon cleavage of N-acetylaspartic acid anhydride by the diethyl ester of glutamic acid.